Thymoma is a neoplasm arising from the epithelial cells of the thymus, classified by Orphanet (Orphanet:99867) and the MONDO Ontology. Recognized morphologic subtypes include types A, AB, B1, B2, and B3, along with metaplastic, micronodular, microscopic, and sclerosing forms. Most thymomas are encapsulated but may invade the thymic capsule, infiltrate surrounding tissues, or metastasize to distant sites. Type B3 is documented as carrying the most aggressive clinical course. Eight distinct subtypes are catalogued, ranging from encapsulated forms to invasive malignant variants.

Per Orphanet-sourced phenotype data, frequent manifestations (30–79% of cases) include chest pain, weight loss, and lymphocyte proliferation abnormalities. Occasional features (5–29%) include dyspnea, cough, night sweats, fever, immunodeficiency, autoimmunity, decreased circulating immunoglobulin concentrations, anti-acetylcholine receptor antibody positivity (associated with co-occurring myasthenia gravis), muscle weakness, and hoarse voice.

No genetic cause or inheritance pattern is certified in this packet. Thymoma originates from thymic epithelial cells; no specific molecular etiology is listed in the certified data sources.

No certified diagnostic methods are documented in this packet. Histopathologic subtype classification into types A, AB, B1, B2, and B3 is intrinsic to the disease definition as characterized by Orphanet.

No FDA-approved therapies or foundational treatment regimens are certified in this packet. Several investigational agents hold FDA orphan drug designations for thymic epithelial tumors, including an anti-PD-1/IL-2 fusion protein, an anti-PDL1/CTLA-4 bispecific antibody, a platinum-based analog ((1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)), and an anti-PDL1 antibody conjugated to a topoisomerase I inhibitor. Milciclib maleate held a prior orphan designation for thymic epithelial tumors but has since been withdrawn. Orphan designation indicates investigational status and does not constitute FDA approval.

Natural history data are not certified in this packet. Per the disease definition, invasive subtypes may infiltrate adjacent structures or metastasize to distant sites; type B3 is documented as carrying the most aggressive clinical course among recognized subtypes.

ClinicalTrials.gov records 10 active or ongoing studies, including Phase 2 investigations of avelumab (NCT03076554), bintrafusp alfa (NCT04417660), PT-112 (NCT05104736), and pembrolizumab (NCT03295227), sponsored by institutions including the National Cancer Institute and M.D. Anderson Cancer Center. The research landscape spans 395 classified publications, predominantly case reports (132) and reviews (65), with documented biomarker and gene therapy research.